key: cord-1011633-ntwl1bsk
authors: Scheidl, Erika; Canseco, Daniel Diez; Hadji‐Naumov, Aleksandar; Bereznai, Benjamin
title: Guillain‐Barré syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature
date: 2020-05-26
journal: J Peripher Nerv Syst
DOI: 10.1111/jns.12382
sha: 2fe28b583545ed8c1b4e0f1554d1851ca7881576
doc_id: 1011633
cord_uid: ntwl1bsk

Acute demyelinating inflammatory polyneuropathy (AIDP) is the most common type of Guillain‐Barré syndrome (GBS) in Europe, following several viral and bacterial infections. Data on AIDP‐patients associated with SARS‐CoV‐2 (coronavirus‐2) infection are scarce. We describe the case of a 54‐years‐old Caucasian female patient with typical clinical and electrophysiological manifestations of AIDP, who was reported positive with PCR for SARS‐CoV‐2, 3 weeks prior to onset of the neurological symptoms. She did not experience a preceding fever or respiratory symptoms, but a transient loss of smell and taste. At the admission to our neurological department, a progressive proximally pronounced paraparesis, areflexia, and sensory loss with tingling of all extremities were found, which began 10 days before. The modified Erasmus Giullain‐Barré Syndrome outcome score (mEGOS) was 3/9 at admission and 1/12 at day 7 of hospitalization. The electrophysiological assessment proved a segmental demyelinating polyneuropathy and cerebrospinal fluid examination showed an albuminocytologic dissociation. The neurological symptoms improved significantly during treatment with immunoglobulins. Our case draws attention to the occurrence of GBS also in patients with COVID‐19 (coronavirus disease 2019), who did not experience respiratory or general symptoms. It emphasizes that SARS‐CoV‐2 induces immunological processes, regardless from the lack of prodromic symptoms. However, it is likely that there is a connection between the severity of the respiratory syndrome and further neurological consequences.

ascending flaccid symmetrical limb paralysis with areflexia, sensory symptoms and often involvement of the cranial nerves. Typical electrodiagnostic features include signs of segmental demyelination as temporal dispersion of the compound muscle action potentials (CMAP) and sensory potentials, prolonged distal motor latencies and reduced conduction velocity in the demyelinative range as well as conduction blocks and absent or prolonged F-waves. 3 A few patients with demyelinating and axonal type of Guillain-Barré syndrome have been reported recently, the onset of neurological symptoms occurred 5 to 10 days after the diagnosis of COVID-19 with respiratory symptoms. [4] [5] [6] [7] [8] 

The 54-year-old, Caucasian female patient with an uneventful medical history was admitted to our neurological department in April 2020 with an acute, proximally pronounced, moderate, symmetric paraparesis (Medical Research Council/MRC/scale was 3/5 proximal and 4/5 distal in the lower extremities). Areflexia, numbness, and tingling of all extremities were also found, with initial maintained gain ability. These symptoms began 3 weeks following a positive reverse-transcriptasepolymerase-chain-reaction (PCR) oropharyngeal test for COVID-19 and were progressing already for 10 days at admission. The test was performed because of her contact to a coronavirus-positive person. She did not experience fever, respiratory or gastrointestinal symptoms, but reported about a transient loss of smell and taste 2 weeks before the GBS symptoms occurred. The modified Erasmus Guillain-Barré Syndrome outcome score (mEGOS) was 3/9 at admission and 1/12 at day 7 of hospitalization pointing to a favorable outcome. The general physical examination was normal, she had no fever and a new PCRoropharyngeal test was negative. Cerebrospinal fluid (CSF) assessment showed an albuminocytologic dissociation with increased protein level (140 g/L) and normal cell count, immunoassay, and Lyme-serology were negative. SARS-Cov-2 RNA was not tested in CSF. Standard laboratory tests (complete blood count, CRP, serum glucose, creatinin, sodium and potassium level, TSH, creatine kinase, and urine test) and special blood tests (Campylobacter jejuni serology, HbA1c, ANA, anti-DNA, c-ANCA, p-ANCA, HIV, serum vitamin B12-level, and serum protein electrophoresis) were also within the normal range. MRI of the cervical spine and the chest x-ray examination did not show pathological findings.

Electrophysiological studies were performed using a Nicolet Viking The clinical and electrophysiological findings of our patient were consistent with AIDP, however, in contrast to the previously reported cases, she did not suffer from preceding fever or respiratory F I G U R E 2 F-wave study of the right tibial nerve with pathological intermediate-latency response (A-wave) symptoms. Nevertheless, she did suffer from transient anosmia and ageusia. The clinical course of the GBS in this case was benign as well.

Seemingly, more serious respiratory symptoms in the acute phase of COVID-19 are associated with a more severe form of GBS, as an indicator of the intensity of pathological immune response. On the other hand, the previous respiratory syndrome might aggravate the GBS-symptoms leading to a worse outcome.

We conclude that GBS occurs also in patients with COVID-19, who did not experience preceding respiratory symptoms or fever. Further studies should be conducted about the connection between early neurological symptoms as anosmia and ageusia and further neurological consequences of COVID-19.

https://orcid.org/0000-0002-5553-3061

Neurological complications of coronavirus and COVID-19

Neurologic features in severe SARS-CoV-2 infection

Giullain-Barre syndrome

Guillain-Barré syndrome associated with SARS-CoV-2

Guillain-Barre syndrome associated with COVID-19 infection: a case report

COVID-19 may induce Guillain-Barré syndrome

Guillain-Barré syndrome following COVID-19: new infection, old complication?

Guillain-Barré syndrome associated with SARS-CoV-2 infection

Miller-Fisher syndrome and polyneuritis cranialis in COVID-19

Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature